Celcuity Inc.
NASDAQCELC enters its most consequential stretch in years with a Phase 3 trial win in hand — and roughly 29% of its float still short. The news broke after market close on May 1. Celcuity announced that its VIKTORIA-1 trial for gedatolisib met its primary endpoint, delivering a clinically meaningful improvement in progression-free survival in the PIK3CA mutant cohort. The company said it…
Snapshot as of 8 May 2026
CELC enters its most consequential stretch in years with a Phase 3 trial win in hand — and roughly 29% of its float still short. The news broke after market close on May 1. Celcuity announced that its VIKTORIA-1 trial…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CELC — free to start on ORTEX.
Sign up for free →Open CELC on ORTEX